Patents Examined by Sean E Aeder
  • Monoclonal antibodies as a medicament for the therapeutic and/or prophylactic treatment of swine-origin influenza A (H1N1) virus (S-OIV) infections
    Patent number: 8486406
    Abstract: The use of monoclonal antibodies Fab28 and Fab49 for the prophylactic or therapeutic treatment of swine-origin influenza A (H1N1) virus (S-OIV) infections is described, the which virus is responsible for the influenza syndrome commonly known as “swine flu”. Moreover, the use of the above-mentioned antibodies for selecting potential vaccines for active immunization against S-OIV is described.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: July 16, 2013
    Assignee: Pomona Ricerca S.R.L.
    Inventors: Roberto Burioni, Massimo Clementi
  • Immunological compositions as cancer therapeutics
    Patent number: 8486413
    Abstract: The present invention concerns antibodies that react immunologically with an epitope comprising VDKSRWQQG (SEQ ID NO: 1), including those that bind to cancer cells, and methods relating thereto. In particular, the antibodies that react immunologically with a particular epitope found in anti-tumor antigen antibodies are not only indicative of favorable therapy using the anti-tumor antigen antibodies, but are therapeutic in and of themselves.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: July 16, 2013
    Assignee: Vanderbilt University
    Inventors: Paula R. Pohlmann, Raymond L. Mernaugh, Carlos L. Arteaga
  • MAP3Ks as modifiers of the p53 pathway and methods of use
    Patent number: 8268548
    Abstract: Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: September 18, 2012
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danix Li, Roel P. Funke
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 8084200
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: December 27, 2011
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Gretchen Frantz, Audrey Goddard, Lino Gonzalez, Austin L. Gurney, Paul Polakis, Andrew Polson, William I. Wood, Thomas D. Wu, Zemin Zhang
  • Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
    Patent number: 8071732
    Abstract: Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, B cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are compositions and methods for use in the identification of cells and biological samples containing one or more hematological malignancy-related compositions, and methods for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as methods for the diagnosis, therapy and/or prevention of a variety of leukemias and lymphomas.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: December 6, 2011
    Assignee: Corixa Corporation
    Inventors: Alexander Gaiger, Paul A. Algate, Jane Mannion, Jonathan D. Clapper, Aijun Wang, Nadia Ordonez, Lauren Carter, Patricia Dianne McNeill
  • ErbB interface peptidomimetics and methods of use thereof
    Patent number: 8057799
    Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: November 15, 2011
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Mark I. Greene, Ramachandran Murali, Hongtao Zhang, Mark Richter, Alan Berezov, Qingdu Liu, Jinqiu Chen
  • Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
    Patent number: 7999088
    Abstract: The present invention provides a method of treating cancer by providing to a subject in need thereof an immunogenic composition comprising a nucleic acid construct encoding a polypeptide comprising CTL epitopes PSMA288-297 and PRAME425-433, or a cross-reactive analogue. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: August 16, 2011
    Assignee: MannKind Corporation
    Inventors: Zhiyong Qiu, Adrian Ion Bot
  • In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
    Patent number: 7981621
    Abstract: The present invention relates to the use of matrix metalloproteinase 7 (MMP-7) and/or its precursors and fragments with MMP-7 immunoreactivity, or of circulating anti-MMP-7 antibodies, as humoral biomarkers in diagnostic in vitro methods for the detection, early detection, monitoring and/or prognosis of renal cell carcinoma (RCC) in human patients.
    Type: Grant
    Filed: August 21, 2006
    Date of Patent: July 19, 2011
    Assignee: Cezanne S.A.S.
    Inventors: Bruno Darbouret, Gaiané Sarkissian
  • Nucleic acid and corresponding protein entitled 161P5C5 useful in treatment and detection of cancer
    Patent number: 7982004
    Abstract: A novel gene (designated 161P5C5) and its encoded protein, and variants thereof, are described wherein 161P5C5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P5C5 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P5C5 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P5C5 can be used in active or passive immunization.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: July 19, 2011
    Assignee: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • Polypeptide compounds for inhibiting angiogenesis and tumor growth
    Patent number: 7977463
    Abstract: In certain embodiments, this present invention provides polypeptide compositions (e.g., antibodies and antigen binding portions thereof that bind to EphB4), and methods for inhibiting EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: July 12, 2011
    Assignee: VasGene Therapeutics, Inc.
    Inventors: Valery Krasnoperov, Nathalie Kertesz, Ramachandra Reddy, Parkash Gill, Sergey Zozulya
  • Cell compositions comprising molecular complexes that modify immune responses
    Patent number: 7973137
    Abstract: Compositions comprising a cell in which a molecular complex with high affinity for its cognate ligand is bound to the surface of the cell are provided. To form the molecular complexes, extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection. Optionally, identical antigenic peptides can be bound to each ligand binding site of a molecular complex.
    Type: Grant
    Filed: August 22, 2000
    Date of Patent: July 5, 2011
    Assignee: Johns Hopkins University
    Inventors: Jonathan Schneck, Sean O'Herrin, Michael S. Lebowitz, Abdel Hamad
  • Nucleic acids and corresponding proteins entitled 191P4D12(b) useful in treatment and detection of cancer
    Patent number: 7968090
    Abstract: A novel gene 191P4D12(b) and its encoded protein, and variants thereof, are described wherein 191P4D12(b) exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 191P4D12(b) provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 191P4D12(b) gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P4D12(b) can be used in active or passive immunization.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: June 28, 2011
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Pia M. Challita-Eid, Aya Jakobovits, Mary Faris, Wangmao Ge
  • Detection of chromosomal region copy number changes to diagnose melanoma
    Patent number: 7960110
    Abstract: This invention provides methods of detecting melanoma. The methods comprises detecting a gain or loss of certain chromosomal regions that undergo copy number changes in melanoma.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: June 14, 2011
    Assignee: The Regents of the University of California
    Inventors: Boris Bastian, Daniel Pinkel
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 7951546
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: May 31, 2011
    Assignee: Genetech, Inc.
    Inventors: Gretchen Frantz, Kenneth J. Hillan, Heidi Phillips, Paul Polakis, Susan D. Spencer, P. Mickey Williams, Thomas D. Wu, Zemin Zhang
  • Gene expression signature for prediction of human cancer progression
    Patent number: 7943306
    Abstract: Methods are provided for classification of cancers by the expression of a set of genes referred to as the core serum response (CSR), or a subset thereof. The expression pattern of the CSR in normal tissues correlates with that seen in quiescent fibroblasts cultured in the absence of serum, while cancer tissues can be classified as having a quiescent or induced CSR signature. Patients with the induced CSR signature have a higher probability of metastasis. Classification according to CSR signature allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: May 17, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Howard Yuan-Hao Chang, Julie Sneddon, Patrick O. Brown
  • Compositions and methods for treating and diagnosing cancer
    Patent number: 7939263
    Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles and signatures associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells. More particularly, the present invention identifies two profiles of cancer stem cells useful for the diagnosis, characterization, and treatment of cancer and cancer metastases. The invention also provides a variety of reagents such as stem cell gene signatures for use in the diagnosis and management of cancer.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: May 10, 2011
    Assignees: The Regents of the University of Michigan, OncoMed Pharmaceuticals, Inc.
    Inventors: Michael F. Clarke, Xinhao Wang, John A. Lewicki, Austin L. Gurney
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 7939268
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: May 10, 2011
    Assignee: Genentech, Inc.
    Inventors: Gretchen Frantz, Kenneth J. Hillan, Heidi Phillips, Paul Polakis, Susan D. Spencer, P. Mickey Williams, Thomas D. Wu, Zemin Zhang
  • Breast cancer related gene ZNFN3A1
    Patent number: 7939254
    Abstract: Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. Also described are methods of treating and preventing breast cancer and breast cancer metastasis as well as methods of assessing the prognosis of a breast cancer subject and the efficacy of a breast cancer therapy. In one embodiment, the diagnostic method involves determining the expression level of ZNFN3A1, a gene whose expression is markedly elevated in breast cancers, that therefore can be used to discriminate between BRC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of BRC, methods of treating BRC and method for vaccinating a subject against BRC.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: May 10, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa, Shuichi Nakatsuru
  • Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
    Patent number: 7939272
    Abstract: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by IGF-1R kinase inhibitors. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to IGF-1R kinase inhibitors.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: May 10, 2011
    Assignee: OSI Pharmaceuticals, Inc.
    Inventor: Elizabeth A. Buck
  • Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
    Patent number: 7935491
    Abstract: A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: May 3, 2011
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Karen Jane Meyrick Morrison, Wangmao Ge, Pia M. Challita-Eid, Aya Jakobovits